Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BETTIS-1: EC-104 Intravitreal Implant vs Ozurdex in Diabetic Macular Edema
NCT06536491Phase 2Active, not recruiting
- Sponsor
- Eclipse Life Sciences
- Start
- Aug 2024
- Primary completion
- Oct 2026
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fluocinolone in diabetic macular edema (DME) (3 arms), sponsored by Eclipse Life Sciences. Primary endpoint: Ocular and Systemic Safety at 24 weeks. Started Aug 2024; status: active, not recruiting.
02
Drugs
fluocinolone
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06536491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536491.